Diabetic Neuropathy – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Diabetic Neuropathy – Pipeline Review, H2 2019’, provides an overview of the Diabetic Neuropathy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Diabetic Neuropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Neuropathy and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.”

Scope


– The report provides a snapshot of the global therapeutic landscape of Diabetic Neuropathy

– The report reviews pipeline therapeutics for Diabetic Neuropathy by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Diabetic Neuropathy therapeutics and enlists all their major and minor projects

– The report assesses Diabetic Neuropathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Diabetic Neuropathy”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Diabetic Neuropathy

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Diabetic Neuropathy pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

“Achelios Therapeutics Inc

Angelini Group

Applied Therapeutics Inc

Arena Pharmaceuticals Inc

Bionevia Pharmaceuticals

Bol Pharma

Bristol-Myers Squibb Co

Calchan Ltd

Celularity Inc

Cleveland Diabetes Care Inc

Commence Bio Inc

CSPC Pharmaceutical Group Ltd

Exodos Life Sciences Limited Partnership

Glycadia Inc

GNT Pharma Co Ltd

Grifols SA

Grunenthal GmbH

Immune Pharmaceuticals Inc

Jiangsu Aosaikang Pharmaceutical Co Ltd

Kineta Inc

Medifron DBT Co Ltd

Mitsubishi Tanabe Pharma Corp

Omeros Corp

Praetego Inc

Reata Pharmaceuticals Inc

Seneca Biopharma Inc

Sichuan Haisco Pharmaceutical Co Ltd

Sonnet BioTherapeutics Inc

Sphaera Pharma Pte Ltd

WEX Pharmaceuticals Inc

Winsantor Inc

YD Life Science Co

Yuhan Corp

Zhejiang Pharmaceutical Co Ltd”

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Diabetic Neuropathy - Overview 6

Diabetic Neuropathy - Therapeutics Development 7

Diabetic Neuropathy - Therapeutics Assessment 15

Diabetic Neuropathy - Companies Involved in Therapeutics Development 23

Diabetic Neuropathy - Drug Profiles 33

Diabetic Neuropathy - Dormant Projects 100

Diabetic Neuropathy - Discontinued Products 103

Diabetic Neuropathy - Product Development Milestones 104

Appendix 113

List of Tables

“List of Tables

Number of Products under Development for Diabetic Neuropathy, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Products under Development by Universities/Institutes, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Diabetic Neuropathy – Pipeline by Achelios Therapeutics Inc, H2 2019

Diabetic Neuropathy – Pipeline by Angelini Group, H2 2019

Diabetic Neuropathy – Dormant Projects, H2 2019

Diabetic Neuropathy – Dormant Projects, H2 2019 (Contd..1), H2 2019

Diabetic Neuropathy – Dormant Projects, H2 2019 (Contd..2), H2 2019

Diabetic Neuropathy – Discontinued Products, H2 2019”

List of Figures

“List of Figures

Number of Products under Development for Diabetic Neuropathy, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products by Top 10 Targets, H2 2019

Number of Products by Stage and Top 10 Targets, H2 2019

Number of Products by Top 10 Mechanism of Actions, H2 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019

Number of Products by Top 10 Routes of Administration, H2 2019

Number of Products by Stage and Top 10 Routes of Administration, H2 2019

Number of Products by Top 10 Molecule Types, H2 2019

Number of Products by Stage and Top 10 Molecule Types, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports